The company has developed rapidly, and has invested 65.438+0.2 billion yuan to build a 654.38+0.2 preparation production line workshop and two API workshops. The production lines of small volume injections, freeze-dried powder injections, capsules, granules, tablets, ointments and suppositories have reached the domestic advanced level. Production scale The annual output of ordinary injection workshop is 6,543,800+0,000, and the annual output of freeze-dried powder injection is 3 million. The annual output of anticancer drug injection workshop is 1 10,000 freeze-dried powder injections and small-volume injections; The annual output of cream100000 and suppository100000 in the workshop for external use. The annual output of the general oral solid preparation workshop is 60 million tablets, 654.38 billion packages of granules and 60 million capsules. Penicillin oral solid preparation workshop has an annual output of 40 million tablets, 50 million packages of dry suspension and 60 million capsules.
At present, the company's product structure has gradually expanded from a single pediatric drug to more than ten departments such as cardiovascular and cerebrovascular department, anti-infection department, digestive department, oncology department, dermatology department and gynecology department, involving more than 40 products. The main products are Chen Gongzaixin, Huafen, Zaijia, black dragon, Weilining and Weilixian. Among them, Chen Gongzaixin was rated as a well-known cold medicine for children in China. Since the listing of 14, it has been well received by doctors and patients.
"Chen Gong Pharmaceutical" is committed to the research, development, production and sales of products such as pediatrics, cardiovascular and cerebrovascular diseases, oncology, infectious diseases, gastroenterology, dermatology and gynecology. After more than ten years of hard work, it has shown a good momentum of development, and the average return on equity in the past three years has reached more than 20%. The products of "Chen Gong Pharmaceutical" are sold all over the country, and the sales revenue is increasing year by year. As the first cold medicine specially designed for children in China, the main product of children's cold medicine "Chen Gongzai Xin" has won wide praise from clinicians and children's parents for its excellent clinical efficacy and good after-sales service, and has long occupied the leading position in the children's cold medicine market. Children's expectorant and antitussive drug-"Huafen", a green OTC product, has scientific formula, contains no addictive components, and is safe and efficient. Clavulanic acid is the first compound preparation of amoxicillin and potassium clavulanate (7: 1) listed in China in 200 1 year, with definite curative effect and little side effects. "aplastic anemia" is one of the four new drugs in China. It is the first isosorbide mononitrate sustained-release tablet approved by the Ministry of Health in China, which is specially used to prevent and treat coronary heart disease and angina pectoris. It was rated as a high-tech product in Jiangsu Province and a national key new product. A number of new products such as "Williamson" went on the market, and the market response was good. In addition, the company has a large number of promising products under development.
Adhering to the concept of "let more people live a better life", the company will actively innovate and strive to develop, and will provide more high-quality products and services.